Company: AEMD
Filing Date: 2025-08-13
Form Type: 10-Q
Source: 0001683168-25-006049
Chunk: 64

Company: AETHLON MEDICAL INC
Filing Date: 2025-08-13
Form: 10-Q
Item: Item 2
Chunk 64
---
 in auditor fees, primarily reflecting
lower audit-related costs compared to the prior period and an $18,118 reduction in contract labor following the completion of a regulatory
project and transition to lower-cost quality management system consultants. These decreases were partially offset by a $41,835 increase
in investor relations expenses related to the special meeting of stockholders.

General and administrative expenses decreased by $16,616
for the three months ended June 30, 2025, primarily due to a $30,789 reduction in insurance costs. This decrease was partially offset
by a $25,853 increase in clinical trial-related expenses, with the remaining variance attributable to a mix of smaller increases and decreases
across multiple categories that netted to an overall decline.

Other (Expense) Income, Net

We recorded other income of $30,532 for the three
months ended June 30, 2025 compared to other income of $49,418 for the three months ended June 30, 2024. Other income in both periods
was primarily interest income.

Net Loss

As a result of the changes in expenses noted above,
our net loss decreased to $1,761,858 in the three months ended June 30, 2025 from $2,571,440 in the three months ended June 30, 2024.

Basic and diluted loss attributable to common stockholders
was ($0.85) for the three months ended June 30, 2025, compared to ($2.76) for the three-month period ended June 30, 2024.

 20 

LIQUIDITY AND CAPITAL RESOURCES

As of June 30, 2025, we had a cash balance of $3,765,154
and working capital of $2,423,421. This compares to a cash balance of $5,501,261 and working capital of $4,050,514 at March 31, 2025.

We do not expect our existing cash as of June 30,
2025, to be sufficient to fund our operations for at least twelve months from the issuance date of these financial statements.

As we expand our activities, our overhead costs to
support personnel, laboratory materials and infrastructure will increase and significant additional financing must be obtained to provide
a sufficient source of operating capital. Should the financing we require to sustain our working capital needs be unavailable to us on
reasonable terms, if at all, when we require it, we may be unable to support our research